Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced approval for additional European clinical trial sites for the ongoing Phase 3 study of buntanetap for the treatment of Parkinson's disease ("PD").
https://finance.yahoo.com/news/annovis-bio-announces-approval-european-123000141.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.